- Achieved high levels of accuracy (91%-100%) for distinguishing adult patients
with URTI, COPD, asthma or pneumonia from subjects with no discernible
respiratory disease
- Demonstrated differential diagnosis of asthma versus COPD, pneumonia
versus asthma and pneumonia versus COPD at 88%-94% accuracy
- Correctly detected lower respiratory tract disease in 84% of adult patients
initially diagnosed as clear by experienced clinicians using stethoscopes
- Finalised clinical protocol and confirmed three leading US hospitals for US
paediatric study, SMARTCOUGH-C
- Forums
- ASX - By Stock
- RAP
- Ann: Further Positive Results From Adult Clinical Study-RAP.AX
Ann: Further Positive Results From Adult Clinical Study-RAP.AX, page-2
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
-
- There are more pages in this discussion • 204 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online